Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

The aberrant tumour vasculature and the associated angiogenic factors have been implicated in tumour immune evasion and progression. Herein, the authors provide their perspectives on how normalization of the tumour microenvironment using antiangiogenic agents could potentially increase the effective...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Clinical oncology 2018-05, Vol.15 (5), p.325-340
Hauptverfasser:	Fukumura, Dai, Kloepper, Jonas, Amoozgar, Zohreh, Duda, Dan G., Jain, Rakesh K.
Format:	Artikel
Sprache:	eng
Schlagworte:	692/699/67/1059/2325 692/699/67/1059/602 692/699/67/2328 692/699/67/322 692/699/67/580 Angiogenesis Angiogenesis inhibitors Angiogenesis Inhibitors - therapeutic use Angiopoietin Antiangiogenic agents Cancer Cancer immunotherapy Cancer research Cancer treatment Carcinogenesis Dosage and administration Drug delivery Effector cells Health aspects Humans Immune checkpoint inhibitors Immune response Immunosuppressive agents Immunotherapy Immunotherapy - trends Medicine & Public Health Metastases Methods Microenvironments Neoplasms - drug therapy Neoplasms - immunology Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - immunology Oncology opinion-2 Physiological aspects Solid tumors T cell receptors Tumor microenvironment Tumor Microenvironment - drug effects Tumor Microenvironment - immunology Tumors Vascular endothelial growth factor Vascular Endothelial Growth Factor A - immunology Vascular Endothelial Growth Factor A - therapeutic use Vesicular Transport Proteins - immunology Vesicular Transport Proteins - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!